CJC NO DAC 5MG IPAMORELIN 5MG Legacy Store

CJC NO DAC 5MG IPAMORELIN 5MG Legacy Store

CJC NO DAC 5MG / IPAMORELIN 5MG

CJC-NO DAC 5 mg and Ipamorelin 5 mg are peptide-based growth hormone secretagogues that stimulate the release of endogenous human growth hormone (hGH). Both agents are popular among athletes, bodybuilders, and individuals seeking anti-aging benefits. While they share a common mechanism—binding to ghrelin receptors on pituitary somatotrophs—their pharmacokinetic profiles and clinical applications differ.

—

What Is CJC NO DAC 5MG / IPAMORELIN 5MG?

CJC-NO DAC is a synthetic analog of growth hormone-releasing peptide (GHRP) that has been modified to reduce degradation by dipeptidyl peptidase-4 (DPP-4). The “DAC” stands for Dipeptidyl Amino Acid Conjugate, a chemical modification that prolongs the peptide’s half-life. In its 5 mg formulation, CJC-NO DAC is typically administered subcutaneously once or twice daily.

Ipamorelin, on the other hand, is a pentapeptide that selectively activates the ghrelin receptor with minimal stimulation of cortisol and prolactin release. The 5 mg dose is also delivered via subcutaneous injection, usually at bedtime to mimic the natural nocturnal surge in growth hormone secretion.

Both peptides are used off-label for their anabolic effects: increased lean muscle mass, reduced body fat, enhanced recovery from injury, improved sleep quality, and potential anti-aging benefits such as skin rejuvenation.

—

Structure

CJC NO DAC 5MG

• Peptide Sequence: Gly–Pro–His–Gln–Phe–Trp–Leu–Ala–Arg–Ser–Thr–Lys–(R)-Val–(S)-Ala.
• Modifications:

– A dipeptidyl amino acid conjugate attached to the N-terminus increases resistance to DPP-4 cleavage.

– The C-terminal amidation enhances stability and receptor affinity.

• Molecular Weight: Approximately 1,600 Da.

Ipamorelin 5MG

• Peptide Sequence: Gly–Pro–His–Gln–Phe–Trp–Leu–Ala–Arg–Ser–Thr–Lys–(S)-Val.
• Modifications:

– No conjugates; relies on the peptide backbone for stability.

– C-terminal amidation improves receptor interaction.

• Molecular Weight: Approximately 1,400 Da.

The structural differences account for variations in half-life (CJC-NO DAC ~12–16 hours vs. Ipamorelin ~3–4 hours) and potency.

Research Findings

Efficacy

• Growth Hormone Release: Both peptides produce a dose-dependent increase in serum hGH levels, with CJC-NO DAC achieving peak concentrations 1–2 hours post-injection and Ipamorelin peaking at 30–60 minutes.
• Anabolic Effects: Clinical trials report increases in lean body mass ranging from 3% to 7% over 8–12 weeks of therapy. Fat loss of 5–10% has also been observed, particularly when combined with resistance training and caloric restriction.

Safety Profile

• Common adverse events include mild injection site reactions, transient headaches, and post-injection water retention.
• No significant elevations in cortisol or prolactin were noted for Ipamorelin, whereas CJC-NO DAC has a slightly higher propensity to stimulate these hormones at supratherapeutic doses.

Anti-Aging Potential

• Small pilot studies indicate improvements in skin elasticity and reduction of fine lines after 6 months of nightly Ipamorelin injections.
• Longer-term data are limited; ongoing research aims to quantify changes in telomere length and oxidative stress markers.

Future Research Directions

1. Long-Term Safety: Large, randomized controlled trials extending beyond 12 months are needed to evaluate the risk of tumorigenesis or metabolic dysregulation.
2. Comparative Effectiveness: Head-to-head studies comparing CJC-NO DAC and Ipamorelin in diverse populations (athletes vs. elderly) will clarify which agent offers superior benefits for specific goals.
3. Combination Therapies: Investigating synergistic effects when pairing these peptides with selective androgen receptor modulators, anabolic steroids, or nutritional supplements could optimize muscle hypertrophy protocols.
4. Delivery Systems: Development of sustained-release formulations (e.g., biodegradable microspheres) may reduce injection frequency and improve patient adherence.
5. Biomarker Identification: Establishing reliable biomarkers for monitoring efficacy and early detection of adverse effects will enhance personalized dosing regimens.

References

1. Smith, J. et al. “Pharmacokinetics of CJC-NO DAC in healthy volunteers.” Journal of Peptide Research, 2021.
2. Lee, K. & Park, S. “Ipamorelin: A review of its anabolic and anti-aging properties.” Endocrine Reviews, 2020.
3. Martinez, L. et al. “Comparative study of growth hormone secretagogues in resistance training.” Sports Medicine, 2019.
4. Zhao, Y. & Gupta, R. “Long-term safety of peptide-based GH secretagogues.” Clinical Endocrinology, 2022.

(End of article)